PHARMAMAR HA OPTADO POR LA RETIRADA DE LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN DE APLIDIN ( PLITIDEPSIN ) ... WITHDRAWAL OF APPLICATIÓN FOR THE MARKETING AUTHORISATION OF APLIDIN ( PLITIDEPSIN ) JULY 23 , 2025 .
Scientists have crafted an experimental vaccine against advanced ovarian cancer that was safe and triggered an immune response using muscled-up blood cells primed by tumors that were taken from the patients.